Hosted on MSN2mon
JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723The company believes that the STAT6 program stands out as a promising ... bispecifics targeting multiple key disease-driving pathways in treating AD and other immune-mediated diseases.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback